Naganuma Makoto, Mizuno Shinta, Nanki Kosaku, Sugimoto Shinya, Kanai Takanori
Department of Gastroenterology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Clin J Gastroenterol. 2016 Dec;9(6):329-336. doi: 10.1007/s12328-016-0686-z. Epub 2016 Oct 3.
Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.
最近,已经开发出几种用于治疗溃疡性结肠炎(UC)的医学疗法,包括5-氨基水杨酸(5-ASA)、皮质类固醇、硫唑嘌呤、钙调神经磷酸酶抑制剂和抗肿瘤坏死因子(TNF)α疗法。本文讨论了包括钙调神经磷酸酶抑制剂和抗TNF治疗在内的难治性UC的治疗选择。此外,还介绍了即将出现的疗法,如戈利木单抗、维多珠单抗、AJM300、托法替布。布地奈德泡沫剂将作为远端结肠炎患者的一种治疗选择。草药,如青黛,对活动性UC也有效,可能对对抗TNFα治疗难治的患者有用。在不久的将来,医生将能够为UC患者使用许多不同的治疗方法。然而,我们不应忘记5-ASA和皮质类固醇作为UC患者的基本治疗方法。